iTeos has initially received exclusive rights to its two targets from the LICR and could potentially receive rights to future targets discovered by LICR. iTeos will leverage LICR’s expertise in tumor immunology and specifically in immunomodulation and immunotherapy, together with LICR’s experience in small molecule drug discovery and in translating its scientific discoveries into preclinical and clinical development projects. This will complement the team of 9 iTeos scientists to execute its therapeutic programs.

 

Licensing

iTeos is dedicated to the discovery of immunomodulators for cancer therapy. In line with its strategic development plan, iTeos is looking for new external projects to complete its own portfolio.
iTeos will be pleased to receive non-confidential data packages describing new drug or target candidates linked to immunomodulation for human cancer therapy. Following an internal review of the package, iTeos will contact you to discuss the next steps.